The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy

被引：3

作者：

Dong, Heng ^{[1
,2
,3
]}

Zhang, Zhengguo ^{[1
,2
,3
]}

Ni, Mengjie ^{[1
,2
,3
]}

Xu, Xiaoyun ^{[1
,2
,3
]}

Luo, Yifeng ^{[1
,2
,3
]}

Wang, Yaru ^{[1
,2
,3
]}

Zhang, Haiyun ^{[1
,2
,3
]}

Chen, Jianxiang ^{[1
,2
,3
,4
]}

机构：

[1] Hangzhou Normal Univ, Sch Pharm, Affiliated Hosp, Hangzhou 311121, Peoples R China

[2] Hangzhou Normal Univ, Affiliated Hosp, Dept Hepatol, Hangzhou 311121, Peoples R China

[3] Hangzhou Normal Univ, Collaborat Innovat Ctr Tradit Chinese Med, Key Lab Elemene Class Anticanc Chinese Med, Engn Lab Dev & Applicat Tradit Chinese Med, Hangzhou 311121, Zhejiang, Peoples R China

[4] Natl Canc Ctr, Div Cellular & Mol Res, Lab Canc Genom, Singapore 169610, Singapore

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2024年 / 25卷 / 10期

基金：

中国国家自然科学基金;

关键词：

Hepatocellular carcinoma; Immunotherapy; Targeted drugs; Combination therapy; SQUAMOUS-CELL CARCINOMA; IMMUNE CHECKPOINT INHIBITORS; OPEN-LABEL; 1ST-LINE TREATMENT; SINGLE-ARM; LIVER-CANCER; TUMOR-GROWTH; DOUBLE-BLIND; LUNG-CANCER; PHASE-II;

D O I：

10.1007/s11864-024-01246-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is a common type of tumor worldwide. The development of systemic treatment of advanced HCC has remained stagnant for a considerable period. During the last years, a series of new treatment regimens based on the combination of immunotherapeutic drugs and targeted drugs have been gradually developed, increased the objective response rate (ORR), overall survival (OS), and progression free survival (PFS) of HCC patients. Among the different combination therapy groups, atezolizumab plus bevacizumab and sintilimab plus IBI-305 seem to have unique advantages, while head-to-head comparisons are still needed. A comprehensive understanding of the developments, the ongoing clinical trials and the mechanisms of combination of immunotherapy and targeted therapy might lead to the development of new combination strategies and solving current challenges such as the molecular biomarkers, the clinical administration order of drugs and the second-line treatments after combination therapy.

引用

页码：1239 / 1256

页数：18

共 143 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2]

Abou-Alfa GK, 2022, NEJM EVID, V1, DOI 10.1056/EVIDoa2100070

[3] TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy [J].

Akalu, Yemsratch T. ;

Rothlin, Carla V. ;

Ghosh, Sourav .

IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :165-177

[4] Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade [J].

Aoki, Tomoko ;

Kudo, Masatoshi ;

Ueshima, Kazuomi ;

Morita, Masahiro ;

Chishina, Hirokazu ;

Takita, Masahiro ;

Hagiwara, Satoru ;

Ida, Hiroshi ;

Minami, Yasunori ;

Tsurusaki, Masakatsu ;

Nishida, Naoshi .

CANCERS, 2020, 12 (10) :1-13

[5] Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer [J].

Bai, Ming ;

Lu, Yao ;

Shi, Chunmei ;

Yang, Jianwei ;

Li, Wei ;

Yin, Xianli ;

Huang, Chenghui ;

Shen, Lin ;

Xie, Liangzhi ;

Ba, Yi .

CANCER BIOLOGY & MEDICINE, 2024, 21 (07) :636-650

[6] Evolving molecularly targeted therapies for advanced-stage thyroid cancers [J].

Bible, Keith C. ;

Ryder, Mabel .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) :403-416

[7] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[8] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[9] Lenvatinib: Role in thyroid cancer and other solid tumors [J].

Cabanillas, Maria E. ;

Habra, Mouhammed Amir .

CANCER TREATMENT REVIEWS, 2016, 42 :47-55

[10] Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma [J].

Campbell, Katie M. ;

Amouzgar, Meelad ;

Pfeiffer, Shannon M. ;

Howes, Timothy R. ;

Medina, Egmidio ;

Travers, Michael ;

Steiner, Gabriela ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Larkin, James ;

Hodi, F. Stephen ;

Boffo, Silvia ;

Salvador, Lisa ;

Tenney, Daniel ;

Tang, Tracy ;

Thompson, Marshall A. ;

Spencer, Christine N. ;

Wells, Daniel K. ;

Ribas, Antoni .

CANCER CELL, 2023, 41 (04) :791-+

← 1 2 3 4 5 6 7 8 9 10 →